Pharmacokinetic Comparison of Selective Prostatic Arterial and Intravenous PSMA PET/CT Radioligand Infusions in Primary Prostatic Adenocarcinoma
- 1 August 2024
- journal article
- research article
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 312 (2) , e232544
Abstract
Selective prostatic arterial infusion yielded higher radiotracer uptake in prostatic tumors than intravenous infusions when using dynamic prostate-specific membrane antigen PET/CT to simulate radioligand therapy.Keywords
This publication has 15 references indexed in Scilit:
- Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate CancerNew England Journal of Medicine, 2021
- Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to ProstatectomyEuropean Urology Focus, 2021
- [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trialThe Lancet, 2021
- Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment OutcomesJournal of Nuclear Medicine, 2018
- Multiple Time-Point 68Ga-PSMA I&T PET/CT for Characterization of Primary Prostate CancerClinical Nuclear Medicine, 2017
- Radiation Dosimetry for177Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor LesionsJournal of Nuclear Medicine, 2016
- PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesionsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2012
- Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastasesEndocrine-Related Cancer, 2011
- Intraindividual Comparison of Selective Arterial versus Venous 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine TumorsClinical Cancer Research, 2010
- MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide TherapyJournal of Nuclear Medicine, 2010